News

LPAI H9N2 virus is widely spread in the Far and Near East. The agent can cause clinical disease and results in grave economic losses due to increased levels of culling, mortality and loss of production capacities of both layers and meat cross-breeds especially in commercial poultry. Over the recent decade H9N2 virus has been widely spread. The infection causes severe damage to the poultry industry. Many countries apply preventive vaccination against H9 low pathogenic avian influenza aimed at reduction of economic risks for the purpose of cost-efficient industry maintenance and control of infection.

In order to meet new threats the Rosselkhoznadzor subordinate FGBI “Federal Centre for Animal Health” has developed and registered two unique preparations against avian influenza caused by H9 virus.

Inactivated emulsion vaccine against avian influenza (H9)

The vaccine is a homogenous emulsion of white color that contains inactivated AI H9 virus and oil adjuvant.

The vaccine induces in chickens the immune response against AI H9 virus in 28 days following single intramuscular vaccination at a dose of 0.5 cm3. The immunity lasts for at least 9 months.

Associated inactivated emulsion vaccine against avian influenza (H9N2) and Newcastle disease

The vaccine is a homogenous emulsion of white color that contains inactivated AI H9 and Newcastle disease viruses and oil adjuvant.

The vaccine induces in chickens the immune response against AI H9 virus and NDV in 28 days following single intramuscular or subcutaneous vaccination at a dose of 0.5 cm3. The immunity lasts for at least 9 months.

The advantage of this vaccine is prevention of two economically significant diseases by means of single dose administration thus reducing technological costs and preventing the birds from additional stress.

AI vaccines are the challenge for the threats interfering with the sustainable development of poultry industry.

FGBI ARRIAH vaccines can be manufactured at request.

FGBI ARRIAH Press-Office